The EMA and Glucagon-Like Peptide-1 Agonists: A Wake-Up Call
1. Abstract The European Medicines Authority (EMA) is a decentralised agency of the European Union (EU) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU and the European economic Area (EEA). On July 11th, 2023, it issued a press release stating that PRAC (The EMA’s safety committee) was reviewing data on the potential risk of suicidal thoughts and thoughts of self-harm with medicines known as GLP-1 receptor agonists, including Ozempic (semaglutide), Saxenda (liraglutide) and Wegovy (semaglutide).
The EMA and Glucagon-Like Peptide-1 Agonists: A Wake-Up Call Read More »